Bellevue Life Sciences Acquisition - Warrants (09/02/2028) Net Income

As of the most recent data (June 2026), BLACW shows a net income of $12M. That compares with $-19M in the prior-year period — up 164.4% year over year. That is below the sector sector average of $98M. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BLACW's net income is now $12M (was $-19M) — a 164.4% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Bellevue Life Sciences Acquisition - Warrants (09/02/2028) is outperforming or lagging.

The its sector sector average net income is about $98M. Bellevue Life Sciences Acquisition - Warrants (09/02/2028) is at $12M, which is lower that average. That is roughly 87.6% below the sector mean. Use the comparison chart on this page to see how BLACW stacks up against individual peers as well.

Tracking BLACW's net income over time shows whether Bellevue Life Sciences Acquisition - Warrants (09/02/2028) is scaling, shrinking, or reshaping that part of the business. The current reading is $12M That compares with $-19M in the prior-year period — up 164.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this net income page, Stockcircle has Bellevue Life Sciences Acquisition - Warrants (09/02/2028)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net income (currently $12M) with ownership activity and broader fundamentals.